Harbor Capital Advisors’s Verve Therapeutics VERV Stock Holding History

Harbor Capital Advisors’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-44,601	Closed	-$501K	–	1499
2025 Q2	$501K	Buy	44,601 +15,625	+54%	+$89.1K	0.02%	523
2025 Q1	$132K	Sell	28,976 -12,568	-30%	-$84.2K	0.01%	638
2024 Q4	$234K	Sell	41,544 -11,980	-22%	-$67.6K	0.01%	639
2024 Q3	$259K	Buy	53,524 +23,565	+79%	+$137K	0.01%	645
2024 Q2	$146K	Sell	29,959 -60	-0.2%	-$377	0.01%	689
2024 Q1	$399K	Buy	+30,019	New	+$398K	0.05%	455

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Harbor Capital Advisors's VERV Position: Q3 2025 in Review

Harbor Capital Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 44,601 shares — an estimated $501K sold.

Harbor Capital Advisors first reported a position in VERV in Q1 2024 and held it in 6 quarters. The position peaked at $501K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Harbor Capital Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Harbor Capital Advisors sold 44,601 Verve Therapeutics shares in Q3 2025, an estimated $501K.
Harbor Capital Advisors first reported a position in Verve Therapeutics in Q1 2024 and held it in 6 quarters.
Harbor Capital Advisors's Verve Therapeutics position peaked at $501K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Harbor Capital Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.